The Expression of c-erbB-2 and P53 Oncoprotein in Endometrial Carcinoma and Its Relationship with Clinical Course and Prognosis
-
摘要: 采用免疫组织化学法检测了64例子宫内膜癌,16例正常子宫内膜,32例子宫内膜增殖症和5例子宫内膜息肉中的C-erbB-2和P53基因蛋白表达情况并分析与其临床病理和预后的关系.结果:(1)c-erbB-2阳性表达率在内膜癌、内膜增殖症和正常内膜分别为60.9%、21.9%和18.8%.内膜息肉无阳性表达.P53阳性表达率则分别为37.5%.3.l%和0.0%.癌组织与增殖症和正常内膜的c-erbB-2和P53阳性表达率相比较,差异均有显著性(P＜O.05).(2)内膜组织中的c-erbB-2和P53的阳性表达与临床分期和组织分级有相关性,而与病理类型,肌层浸润无关.(3)P53和c-erbB-2表达阳性内膜癌患者的3、5年生存率明显低于阴性患者.上述结果表明,c-erbB-2和P53与内膜癌的发生,发展密切相关,可作为评估其恶性生物学行为和预后的重要指标之一.Abstract: Expression of c-erbB-2 and P53 oncoprotein was examined by immunohistochemistry in paraffin sections from 64 cases of endometrial carcinoma,16 cases of noraml endometrium,32 cases of endometium hyperplasia and 5 cases endometrium polyp.The results showed;(l)The positive rate of expression of c-erbB-2 and P53 in endometrial carcinoma were 60.9% and 37.5% respectively.They were significantly higher than normal endometrium,endometium hyperplasia and endometrium polyp.(2)The positive expression of c-erbB-2 and P53 in endometrial carcinoma were associated with clinical stage and histologic grade,but not with pathologic type and depth of muscle invasion.(3)The 3 or 5 year survival rate of patient with the positive expressin of c-erbB-2 and P53 were significantly lower than that wilh the negative expression.These results suggested that c-erbB-2 and P53 were valuable maker to understand the dgree of mailigancy and evaluate prognosis of disease.
-
Key words:
- Endometrial naplasm /
- gene /
- c-erbB-2 /
- P53 /
- immunohistochemistry Prognosis
-
-
1. Jaechno J,Urmacher C,Thaler H,et al.Expression of HER-2/neu oncogene product P185 in correlation of clinicopathological and prognostic fa-cters of gastic carcinoma.J Cancer Clin Oncol,1992,113:474. 2. Miller AB,Hoogestraten B,Stacuet M,et al.Reporting results of cancer treat-ment.Cancer,1981,47:207. 3. Mizatani T,Onda M,Tokanage A,et al.Relationship of c-erbB-2 protein expression and gene amplification to inva-sion and metastasis in human gastric cancer.Cancer,1995,72:2083. 4. Fisher CJ,Clillett CE,Vojese KB,et al.Problem with P53 immunohistoche-mical staining the effect of fixation and variation in the method of evaluation.Br J Cancer,1994,69:26. 5. Simon DJ,Godolphin W,Jones LA, et al.Studies of the HER-2/neu protooncogene in human breast and ovarian cancer.Science,1989,224:701. 6. Teneriello MG,Ebina M,Linnoila R I,et al.P53 and K-ras gene mutations in epithelial ovarian neoplasms.Cancer Res,1993,53:3103. 7. Bigsby RM,Li A,Romalaski J,et al.Immunoh-istrochemical study of HER-2/neu,epidermal growth factor receptor and steroid receptor exprssion in normal and malignant endometrium. Obstet Gynecol,1992,79:95. 8. Berchuck K,Rodriguez G,Kinnry RB,et al.Oversxpression of HER-2/neu in endometrial cancer is associated with advanc-ed stage disease.Am J Obstet Gynecol,1991,154:15
计量
- 文章访问数:
- HTML全文浏览量: 0
- PDF下载量:
下载:
